Overview
Eli Lilly combines a broad medicines portfolio with strong reported growth, particularly in cardiometabolic health. The shares recently traded at $1,142.85, with a market capitalisation of 1.0T. Its scale and 33.53% profit margin sit alongside a high earnings multiple, making the durability of growth an important part of the investment story.
Eli Lilly is a large US-based pharmaceutical company with a broad portfolio spanning diabetes and obesity care, oncology, immunology and other health conditions. Its cardiometabolic medicines include Mounjaro, Zepbound, Trulicity and a range of insulin products; it also sells treatments in areas such as cancer, migraine and immune disorders. The company operates across the United States and international markets. This breadth gives it exposure to several therapeutic areas, while its product development and commercial success remain central to its business.
Key facts
- Ticker
- LLY
- Exchange
- US
- ISIN
- US5324571083
- Sector
- Healthcare
- Industry
- Drug Manufacturers – General
- Country
- USA
- Currency
- USD
- Price
- $1,142.85
- Previous close
- $1,149.85
- Day change
- -$7.00 (-0.61%)
- Market cap
- 1.0T
- 52W low
- $778.94
- 52W high
- $1,292.65
Price and trend
Last price: $1,142.85
- Price
- $1,142.85
- 52W range
- $778.94 – $1,292.65
- 50-day SMA
- $1,177.91
- 200-day SMA
- $1,072.80
- Price vs 50D SMA
- -2.98%
- Price vs 200D SMA
- 6.53%
Valuation
- P/E
- 38.91
- PEG
- 1.14
- EPS
- 29.55
- Dividend yield
- 0.56%
- Beta
- 0.50
At a market capitalisation of 1.0T, Eli Lilly is a very large pharmaceutical business. Its price-to-earnings ratio of about 38.9 is demanding, although the PEG ratio of about 1.14 provides another lens on valuation in the context of growth. The supplied figures pair that valuation with 47.70% revenue growth and a 33.53% profit margin. Whether the shares can justify their multiple depends on the company sustaining growth and translating its portfolio and development pipeline into durable earnings. The 0.56% dividend yield is modest.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Profitability and growth
- Revenue growth
- 47.70%
- Revenue TTM
- 79.7B
- Profit margin
- 33.53%
Analyst view
Comparison uses the last price shown; targets are analyst estimates.
- Price
- $1,142.85
- Target price
- $1,328.83
- Target vs last price
- 16.27% from last price
- Rating
- 4.3667
- Analysts
- 30
- strong_buy_count
- 19
- buy_count
- 6
- hold_count
- 3
- sell_count
- 1
- strong_sell_count
- 1
Analyst views are mostly positive in the supplied breakdown: 19 are listed as strong buy and six as buy, alongside three holds, one sell and one strong sell. The average target price is $1,328.83, equivalent to 16.27% from the last price. These are secondary indicators and do not remove the business and valuation risks facing the shares.
Risks
Eli Lilly’s growth prospects depend on maintaining demand for key medicines while developing additional products and navigating competition, clinical development, manufacturing and regulatory requirements. A substantial valuation means expectations for continued earnings growth are important; disappointment could weigh on the shares. The 52-week range also reflects meaningful share-price movement, while the modest dividend yield offers limited income relative to the company’s growth-oriented profile.
FAQ
What does Eli Lilly do?
Eli Lilly develops, manufactures and sells medicines across cardiometabolic health, oncology, immunology, migraine and other areas. Its portfolio includes treatments for type 2 diabetes and obesity, as well as products for cancer and immune-related conditions.
How has Eli Lilly been growing?
The supplied figures show revenue growth of 47.70% and trailing twelve-month revenue of $79.7 billion. Growth is supported by a broad medicines portfolio, including products in diabetes and obesity care.
Does Eli Lilly pay a dividend?
Eli Lilly has a dividend yield of 0.56%. The yield is modest, so the shares’ investment profile is more closely tied to the company’s earnings and growth prospects than to current income.
What are the main risks of investing in Eli Lilly?
Risks include the challenge of sustaining growth as products face competition, the need to develop and commercialise new medicines, and dependence on successful research, manufacturing and regulatory outcomes. The shares also trade at a high earnings multiple, which can make valuation sensitive to changes in growth expectations.
*This content is aimed to provide general information only, and does not take your personal objectives, financial situation or needs into account.
